Actuate Therapeutics, Inc. (ACTU)
NASDAQ · Manufacturing · Pharmaceutical preparations
$0.6800+$0.0600 (+9.68%) on the dayAs of the close; data may be delayed.
ACTU price, last 12 months
Key stats
- Previous close
- $0.6200
- Open
- $0.6500
- Day range
- $0.6401 – $0.7499
- 52-week range
- $0.6095 – $8.49
- Volume
- 383.4K
- Avg volume (20 days)
- 289.8K
- Market cap
- $16.3M
Performance
1W−30.7%
1M−61.8%
3M−59.5%
6M−70.0%
YTD−88.9%
1Y−90.3%
vs S&P 500, 1Y−107.1 pts
Technicals and fundamentals
About Actuate Therapeutics, Inc.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $16.3M